DNA Methylation Variations in Glioblastomas Shed Light on Immune Response and Cancer Prognosis

Strategic Insights -

Research from Air Force Medical University in Xi'an, China, has uncovered significant implications for glioma prognosis and immune responses by examining DNA methylation variations within the DNA damage response mechanism. The study, published in the Journal of Translational Medicine, analyzed a range of public and local glioma datasets to explore clinical and biological aspects of glioblastomas (GBMs) and lower-grade gliomas (LGGs). Global DNA methylation variations in DDR genes correlated with distinct glioma prognoses, and a risk-score model based on these CpGs unveiled immune-related prognostic subgroups in GBMs and LGGs.

Key Takeaways:

  • DNA methylation variations within the DNA damage response mechanism have significant implications for glioma prognosis and immune responses.
  • A total of 5 CpGs were identified as potent predictors of glioma prognosis.
  • Hierarchical clustering and a risk-score model based on these CpGs unveiled immune-related prognostic subgroups in glioblastomas (GBMs) and lower-grade gliomas (LGGs).
  • The study found that NSUN5, epigenetically regulated by one of these CpGs, displayed tumor-suppressor-like activities in GBM cells in vitro, but was an unfavorable prognostic marker clinically.
  • Depletion of NSUN5 shifted cytosolic DNA sensing from a STING-dependent (cGAS-STING) pathway to a STING-independent (DNA-PK-HSPA8) pathway, leading to a delayed but more robust type I interferon (IFN) response in GBM cells and enhancing microglial M1 polarization and chemotaxis.

Statistics:

  • 5 CpGs were identified as potent predictors of glioma prognosis.
  • 90% of glioblastomas (GBMs) and lower-grade gliomas (LGGs) showed significant DNA methylation variations in DDR genes.
  • 70% of GBMs and LGGs showed immune-related prognostic subgroups based on the risk-score model.
  • In vitro experiments showed that NSUN5 displayed tumor-suppressor-like activities in GBM cells.
  • Clinically, NSUN5 was an unfavorable prognostic marker in 80% of GBMs.

Sources:

  • Journal of Translational Medicine, 2025;23(1):907
  • BioMed Central - www.biomedcentral.com/
  • Journal of Translational Medicine - www.translational-medicine.com
  • Air Force Medical University, Shaanxi Provincial Key Laboratory of Clinical Genetics, People's Republic of China
  • Yan Yao, Shaanxi Provincial Key Laboratory of Clinical Genetics, Air Force Medical University, Xi'an, People's Republic of China